Target intelligence / Profile preview

Group B Streptococcus alpha-like protein 1 N-terminal domain (Alp1N)

Target
Alp1N
Molecular classification
Other
01

Overview

The Group B Streptococcus alpha-like protein 1 N-terminal domain (Alp1N) is a key surface-anchored protein domain of Streptococcus agalactiae (Group B Streptococcus, or GBS). GBS is a leading cause of neonatal sepsis, meningitis, and pneumonia, as well as adverse pregnancy outcomes like stillbirth and preterm delivery. The Alp1 protein belongs to the alpha-like protein (Alp) family, which are chimeras with a mosaic structure. The N-terminal domain of Alp1 protrudes through the bacterial polysaccharide capsule and is highly immunogenic and functionally active, playing a role in host cell adhesion and invasion by binding to glycosaminoglycans and integrins. Because of its extracellular exposure and conservation across clinical isolates, Alp1N is a major target for vaccine development. MinervaX is developing a recombinant protein-based vaccine candidate, GBS-AlpN (also known as GBS-NN/NN2), which incorporates the N-terminal domains of AlphaC, Rib, Alp1, and Alp2/3 to elicit protective maternal antibodies that cross the placenta and protect newborns.

Other names
Alp1 N-terminal domainAlpha-like protein 1 N-terminal domainAlp1-NGBS Alp1NStreptococcus agalactiae alpha-like protein 1 N-terminal domain
02

Mechanism of action

Active immunization to induce protective maternal IgG antibodies that cross the placenta and mediate opsonophagocytic killing of Group B Streptococcus expressing Alp1

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Injection site painErythemaSwellingSystemic reactogenicity
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

Anti-Alp1N IgG antibody concentrationOpsonophagocytic killing assay (OPKA) titer

Beyond the preview

Go deeper on Group B Streptococcus alpha-like protein 1 N-terminal domain (Alp1N).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Group B Streptococcus alpha-like protein 1 N-terminal domain (Alp1N).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call